Stock Events

Jacobio Pharmaceuticals. 

HK$2.44
1
-HK$0.01-0.41% Today

Statistics

Day High
2.46
Day Low
2.38
52W High
10.48
52W Low
2.16
Volume
345,300
Avg. Volume
1,572,006
Mkt Cap
4.9B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MarExpected
Q4 2020
Q1 2021
Q2 2021
Q2 2023
Next
-0.32
-0.21
-0.11
0
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1167.HK. It's not an investment recommendation.

About

Jacobio Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, focusing on the in-house discovery and development of oncology therapies. The company's lead drug development programs include two clinical-stage allosteric Src homology region 2 domain-containing phosphatase-2 (SHP2) inhibitors comprising JAB-3312 and JAB-3068 for the treatment of esophageal cancer; JAB-8263, a small molecule inhibitor of BET family proteins regulating MYC transcription to treat various cancers; and JAB-21822, an oral small molecule targeting mutant KRAS G12C protein. It is also develops JAB-BX102, a humanized inhibitory antibody against human CD73 for the treatment of PD-1 resistant cancer; JAB-6343, an inhibitor that targets fibroblast growth factor receptor 4 for advanced hepatocellular carcinoma with FGF19 overexpression; JAB-2485, an aurora A kinase inhibitor for solid tumors; JAB-24114, a tumor metabolic pathway for the treatment of solid tumors; and JAB-BX300, a molecule antibody targeting RAS pathway to treat pancreatic and other solid tumors with KRAS mutations. The company has a strategic collaboration with AbbVie Ireland Unlimited Company to develop and commercialize SHP2 inhibitors. Jacobio Pharmaceuticals Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, China.
Show more...
CEO
Dr. Yinxiang Wang
Employees
285
Country
Hong Kong
ISIN
KYG4987A1094

Listings